Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

C. Fernandez-Rozadilla; J. B. Cazier; V. Moreno; M. Crous-Bou; E. Guinó; G. Durán; M. J. Lamas; R. López; S. Candamio; E. Gallardo; L. Paré; M. Baiget; D. Páez; L. A. López-Fernández; L. Cortejoso; M. I. García; L. Bujanda; D. González; V. Gonzalo; L. Rodrigo; J. M. Reñé; R. Jover; A. Brea-Fernández; M. Andreu; X. Bessa; X. Llor; R. Xicola; C. Palles; I. Tomlinson; S. Castellví-Bel; A. Castells; C. Ruiz-Ponte; A. Carracedo

doi:10.1038/tpj.2012.2

Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

C. Fernandez-Rozadilla, J. B. Cazier, V. Moreno, M. Crous-Bou, E. Guinó, G. Durán, M. J. Lamas, R. López, S. Candamio, E. Gallardo, L. Paré, M. Baiget, D. Páez, L. A. López-Fernández, L. Cortejoso, M. I. García, L. Bujanda, D. González, V. Gonzalo, L. RodrigoJ. M. Reñé, R. Jover, A. Brea-Fernández, M. Andreu, X. Bessa, X. Llor, R. Xicola, C. Palles, I. Tomlinson, S. Castellví-Bel, A. Castells, C. Ruiz-Ponte, A. Carracedo

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

40 Citations (Scopus)

Abstract

The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale. © 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13.

Original language	English
Pages (from-to)	209-217
Journal	Pharmacogenomics Journal
Volume	13
Issue number	3
DOIs	https://doi.org/10.1038/tpj.2012.2
Publication status	Published - 1 Jun 2013

Keywords

5-fluorouracil
ADR
colorectal cancer
FOLFOX
GWAS

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/tpj.2012.2

Cite this

Fernandez-Rozadilla, C., Cazier, J. B., Moreno, V., Crous-Bou, M., Guinó, E., Durán, G., Lamas, M. J., López, R., Candamio, S., Gallardo, E., Paré, L., Baiget, M., Páez, D., López-Fernández, L. A., Cortejoso, L., García, M. I., Bujanda, L., González, D., Gonzalo, V., ... Carracedo, A. (2013). Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics Journal, 13(3), 209-217. https://doi.org/10.1038/tpj.2012.2

@article{1a0e37c7d55d45ccba74631aaad1132b,

title = "Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration",

abstract = "The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale. {\textcopyright} 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13.",

keywords = "5-fluorouracil, ADR, colorectal cancer, FOLFOX, GWAS",

author = "C. Fernandez-Rozadilla and Cazier, {J. B.} and V. Moreno and M. Crous-Bou and E. Guin{\'o} and G. Dur{\'a}n and Lamas, {M. J.} and R. L{\'o}pez and S. Candamio and E. Gallardo and L. Par{\'e} and M. Baiget and D. P{\'a}ez and L{\'o}pez-Fern{\'a}ndez, {L. A.} and L. Cortejoso and Garc{\'i}a, {M. I.} and L. Bujanda and D. Gonz{\'a}lez and V. Gonzalo and L. Rodrigo and Re{\~n}{\'e}, {J. M.} and R. Jover and A. Brea-Fern{\'a}ndez and M. Andreu and X. Bessa and X. Llor and R. Xicola and C. Palles and I. Tomlinson and S. Castellv{\'i}-Bel and A. Castells and C. Ruiz-Ponte and A. Carracedo",

year = "2013",

month = jun,

day = "1",

doi = "10.1038/tpj.2012.2",

language = "English",

volume = "13",

pages = "209--217",

journal = "Pharmacogenomics Journal",

issn = "1470-269X",

number = "3",

}

Fernandez-Rozadilla, C, Cazier, JB, Moreno, V, Crous-Bou, M, Guinó, E, Durán, G, Lamas, MJ, López, R, Candamio, S, Gallardo, E, Paré, L, Baiget, M, Páez, D, López-Fernández, LA, Cortejoso, L, García, MI, Bujanda, L, González, D, Gonzalo, V, Rodrigo, L, Reñé, JM, Jover, R, Brea-Fernández, A, Andreu, M, Bessa, X, Llor, X, Xicola, R, Palles, C, Tomlinson, I, Castellví-Bel, S, Castells, A, Ruiz-Ponte, C & Carracedo, A 2013, 'Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration', Pharmacogenomics Journal, vol. 13, no. 3, pp. 209-217. https://doi.org/10.1038/tpj.2012.2

TY - JOUR

T1 - Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

AU - Fernandez-Rozadilla, C.

AU - Cazier, J. B.

AU - Moreno, V.

AU - Crous-Bou, M.

AU - Guinó, E.

AU - Durán, G.

AU - Lamas, M. J.

AU - López, R.

AU - Candamio, S.

AU - Gallardo, E.

AU - Paré, L.

AU - Baiget, M.

AU - Páez, D.

AU - López-Fernández, L. A.

AU - Cortejoso, L.

AU - García, M. I.

AU - Bujanda, L.

AU - González, D.

AU - Gonzalo, V.

AU - Rodrigo, L.

AU - Reñé, J. M.

AU - Jover, R.

AU - Brea-Fernández, A.

AU - Andreu, M.

AU - Bessa, X.

AU - Llor, X.

AU - Xicola, R.

AU - Palles, C.

AU - Tomlinson, I.

AU - Castellví-Bel, S.

AU - Castells, A.

AU - Ruiz-Ponte, C.

AU - Carracedo, A.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale. © 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13.

AB - The development of genotyping technologies has allowed for wider screening for inherited causes of variable outcomes following drug administration. We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX). A validation set of 791 patients was also studied. Seven SNPs (rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568 and rs4243761) showed evidence of association (pooled P-values 0.020, 9.426E-03, 0.010, 0.017, 0.042, 2.302E-04, 2.803E-03) with adverse drug reactions (ADRs). This is the first study to explore the genetic basis of inter-individual variation in toxicity responses to the administration of 5-FU or FOLFOX in CRC patients on a genome-wide scale. © 2013 Macmillan Publishers Limited. All rights reserved 1470-269X/13.

KW - 5-fluorouracil

KW - ADR

KW - colorectal cancer

KW - FOLFOX

KW - GWAS

U2 - 10.1038/tpj.2012.2

DO - 10.1038/tpj.2012.2

M3 - Article

SN - 1470-269X

VL - 13

SP - 209

EP - 217

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

IS - 3

ER -

Pharmacogenomics in colorectal cancer: A genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this